improve IBD drug tolerability
giiant pharma develops gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of inflammatory bowel diseases (IBD). Precision delivery remains a central focus for the development of new drug therapeutics, with limited systemic exposure for a safer profile while maximizing local action to improve IBD patient care.
orally-delivered | gut-restricted
giiant pharma‘s GastroIntestinal-Induced ANTi-inflammatory technology is a uniquely targeted delivery strategy, developed by two former Merck Frosst scientists, using the bacterial activity of the gut microbiota to bioactivate and release the active drug substance at specific locations in the lower GI tract.
Although orally-delivered, giiant’s drug candidates are not systemically absorbed but remain able to achieve high drug concentrations in the colonic area.
giiant pharma aims to become a GI leader in precision delivery technologies, with the ability to develop safer, patient-tailored drug therapeutics with local, tissue-specific delivery or bioactivation. These efforts should provide optimal treatment modalities to patients for various GI diseases and conditions.